-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on NovoCure, Raises Price Target to $42

Benzinga·12/13/2024 13:12:54
Listen to the news
Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:NVCR) with a Overweight and raises the price target from $28 to $42.